Whalesbook
Geopolitical Tensions aur Pharma exports ka chakravyuh
Dekho, India ki pharma industry ko apni supply chains ko mazboot karna padega aur global uncertainty se apne exports ko bachana hoga. Commerce Secretary Rajesh Agarwal ne bola hai ki jitna ho sake, import kiye hue raw materials aur APIs (Active Pharmaceutical Ingredients) par dependance kam karni chahiye, bhale hi poori tarah se substitute na ho paye. Yeh sab isliye zaroori hai kyunki regions mein chal rahe conflicts ki wajah se shipping costs badh rahi hain aur trade routes ko khatra hai. Is sabka asar Nifty Pharma index par bhi dikh raha hai, jo last week 3.2% aur last month 5% gir gaya hai.
Biosimilars mein growth, par API costs ka load
API imports kam karne par focus toh hai hi, lekin India ka pharma sector biosimilars jaise high-value segments mein bhi kaafi aage badh raha hai. Indian biosimilars market 2026 mein ₹184 million se badhkar 2035 tak over $1 billion ho sakta hai. Yeh growth chronic diseases aur affordable biologics ki demand se chalegi. Yeh segment future mein value dega, API sector ke opposite jo import par nirbhar hai. China abhi bhi top API producer hai, lekin India ke paas sabse zyada API Drug Master Files (DMFs) hain. Par 2024 mein China ne naye DMF filings mein India ko peeche chhod diya hai. India ka APIs aur intermediates, jismein kaafi kuch China se aata hai, par bharosa current geopolitical tensions ke karan sirf exports ko hi nahi, balki domestic manufacturing costs ko bhi badha raha hai.
Global shocks se exports aur valuations ko risk
Global instability aur badhi hui shipping costs India ke pharma exports ke liye ek bada threat ban gayi hain. West Asia mein conflict ke karan freight charges already double ho gaye hain, jisse har shipment par $4,000-$8,000 ka extra kharcha aa raha hai aur profit margins tight ho rahe hain. Industry ka estimate hai ki agar yeh disruption chalti rahi, toh March mein Gulf Cooperation Council (GCC) aur West Asia/North Africa (WANA) regions mein hone wali exports se ₹2,500 Crore se lekar ₹5,000 Crore tak ka nuksaan ho sakta hai. Yeh badhi hui costs khaas kar temperature-sensitive medicines ke liye pareshani badha sakti hain aur India ki competitive pricing, especially generic drugs ke liye, kamzor kar sakti hai. Sun Pharmaceutical Industries aur Torrent Pharmaceuticals jaise companies ka financials achha hone ke baad bhi, unke stock valuations kaafi high lag rahe hain. Sun Pharma ka P/E ratio lagbhag 37.99x hai, aur Torrent ka 58.5x, jo industry average se kaafi zyada hain. Isse supply chain problems ke karan earnings mein kami ke liye zyada scope nahi bachta. Sector ka overall P/E ratio around 31.6x hai, jo abhi bhi high growth expectations dikha raha hai.
Future growth ke liye cautious optimism
Halanki abhi challenges hain, India ke pharma sector ka future outlook overall positive hai. Ratings agency ICRA ne "Stable" outlook maintain kiya hai aur fiscal year 2026 mein 7-9% revenue growth predict kiya hai, jismein domestic demand aur European markets se gains ka support milega. Overall industry earnings mein saalana 17% tak growth expect hai, jo resilience dikhata hai. Sector ko apna poora potential achieve karne ke liye, current geopolitical risks ko carefully manage karna hoga, key inputs ke liye sources diversify karne honge, aur long-term competitiveness maintain karne ke liye biosimilars jaise high-growth areas mein invest karna hoga.